9(R)-HETE constitutes 50% of the racemic (±)9-HETE mixture and acts as an RXRγ agonist, inducing a 1.5-fold transcriptional activation at 300 nM. Its stereochemistry is assigned via chiral HPLC. This eicosanoid is used in vitro to study nuclear receptor signaling and lipid mediator pathways in inflammation and metabolism research.